
SIOUX FALLS, S.D., Dec. 2, 2011 /PRNewswire/ -- An innovative South Dakota pharmaceutical company, pharmaCline™, has launched its "pharmaCline Can Help" advertising campaign with a bold statement. On November 23, 2011, pharmaCline became a part of the New York City scenery with a video spot on the CBS jumbo screen located in Times Square. The advertisement will be aired from November 23 through January 1, 2012.
(Logo: http://photos.prnewswire.com/prnh/20111202/MN16158LOGO)
This short video is the first of multiple advertisements to promote the message "pharmaCline Can Help". pharmaCline will use this campaign to educate the public about the risks of infection, the danger of ignoring infection and the risk of antibiotic resistance.
The video may be viewed online at http://pharmacline.com/news/pharmacline-launches-its-pharmacline-can-help-advertising-campaign.
"The sheer size of the population that is at increased risk of infection is alarming," said Catherine Sommervold, pharmaCline's Vice President for Development and Patient Outreach.
50 Million Americans are at a high risk of contracting an infection from normal daily activities. Often minor cuts, scrapes and burns become infected and turn into life threatening situations. Many of these infections can be avoided by use of effective antibiotics. pharmaCline's three FDA-listed antibiotics help to kill infections before they become serious problems for those affected.
In the United States 100,000 people die every year from hospital related infections. Treatment of infections can result in high health care costs for patients and health care systems.
"Helping people understand that highly effective antibiotics are available at a low price is a goal of this campaign," said Sommervold.
pharmaCline helps to reduce these costs by offering highly effective broad spectrum antibiotics, Diabecline®, Tissecline® and TisseclinePlus®, for under $40 per 100 doses. More information about pharmaCline and its innovative products can be found at www.pharmacline.com
SOURCE pharmaCline
Share this article